Myostatin Inhibition in Muscle, but Not Adipose Tissue, Decreases Fat Mass and Improves Insulin Sensitivity
Top Cited Papers
Open Access
- 19 March 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (3) , e4937
- https://doi.org/10.1371/journal.pone.0004937
Abstract
Myostatin (Mstn) is a secreted growth factor expressed in skeletal muscle and adipose tissue that negatively regulates skeletal muscle mass. Mstn−/− mice have a dramatic increase in muscle mass, reduction in fat mass, and resistance to diet-induced and genetic obesity. To determine how Mstn deletion causes reduced adiposity and resistance to obesity, we analyzed substrate utilization and insulin sensitivity in Mstn−/− mice fed a standard chow. Despite reduced lipid oxidation in skeletal muscle, Mstn−/− mice had no change in the rate of whole body lipid oxidation. In contrast, Mstn−/− mice had increased glucose utilization and insulin sensitivity as measured by indirect calorimetry, glucose and insulin tolerance tests, and hyperinsulinemic-euglycemic clamp. To determine whether these metabolic effects were due primarily to the loss of myostatin signaling in muscle or adipose tissue, we compared two transgenic mouse lines carrying a dominant negative activin IIB receptor expressed specifically in adipocytes or skeletal muscle. We found that inhibition of myostatin signaling in adipose tissue had no effect on body composition, weight gain, or glucose and insulin tolerance in mice fed a standard diet or a high-fat diet. In contrast, inhibition of myostatin signaling in skeletal muscle, like Mstn deletion, resulted in increased lean mass, decreased fat mass, improved glucose metabolism on standard and high-fat diets, and resistance to diet-induced obesity. Our results demonstrate that Mstn−/− mice have an increase in insulin sensitivity and glucose uptake, and that the reduction in adipose tissue mass in Mstn−/− mice is an indirect result of metabolic changes in skeletal muscle. These data suggest that increasing muscle mass by administration of myostatin antagonists may be a promising therapeutic target for treating patients with obesity or diabetes.Keywords
This publication has 50 references indexed in Scilit:
- Myostatin promotes the terminal differentiation of embryonic muscle progenitorsGenes & Development, 2008
- Genetic Analysis of the Role of Proteolysis in the Activation of Latent MyostatinPLOS ONE, 2008
- Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese MiceCell Metabolism, 2008
- FSTL3 deletion reveals roles for TGF-β family ligands in glucose and fat homeostasis in adultsProceedings of the National Academy of Sciences, 2007
- Myostatin modulates adipogenesis to generate adipocytes with favorable metabolic effectsProceedings of the National Academy of Sciences, 2006
- Myostatin Regulates Cardiomyocyte Growth Through Modulation of Akt SignalingCirculation Research, 2006
- Resistance to body fat gain in ‘double-muscled’ mice fed a high-fat dietInternational Journal of Obesity, 2006
- Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid HypertrophyMolecular and Cellular Biology, 2004
- Myostatin Knockout in Mice Increases Myogenesis and Decreases AdipogenesisBiochemical and Biophysical Research Communications, 2002
- Inhibition of Preadipocyte Differentiation by Myostatin Treatment in 3T3-L1 CulturesBiochemical and Biophysical Research Communications, 2001